Publications

Drug delivery

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

31-12-2026

Therapeutic drug monitoring

Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.

01-10-2026

The oncologist

The insufficient publication of early-phase clinical trials in oncology.

12-09-2026

Clinical pharmacokinetics

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

01-09-2026

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Unexpected Lack of Efficacy of Liposomal-Encapsulated Daunorubicin/Cytarabine in Pediatric FLT3 Wild-Type Newly Diagnosed AML.

05-08-2026

Cancer chemotherapy and pharmacology

Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review.

03-08-2026

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Prestin as a potential biomarker for cochlear injury: Current evidence and future directions.

01-08-2026

CPT: pharmacometrics & systems pharmacology

Extrapolating Vincristine-Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias.

01-08-2026

Tumori

Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.

30-07-2026

Acta oncologica (Stockholm, Sweden)

The impact of pazopanib and extremity radiotherapy on transaminase elevations in soft tissue sarcoma.

28-07-2026

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC.

16-07-2026

Cancer chemotherapy and pharmacology

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

06-07-2026

The Lancet. Oncology

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

01-07-2026

Ear and hearing

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

26-06-2026

European journal of cancer (Oxford, England : 1990)

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

18-06-2026

Pharmacogenomics

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

10-06-2026

British journal of clinical pharmacology

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

01-06-2026

British journal of clinical pharmacology

Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.

01-06-2026

British journal of cancer

Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.

01-06-2026

Cancer communications (London, England)

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

25-05-2026

Cancer chemotherapy and pharmacology

Transfer of trastuzumab and pertuzumab into human breast milk: a case report.

20-05-2026

Clinical pharmacokinetics

Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours.

01-05-2026

Bone marrow transplantation

Risk factors for alloimmune lung syndromes after allogeneic hematopoietic cell transplantation in children.

01-05-2026

Pharmacogenomics

Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report.

13-04-2026

Clinical and translational science

Analytical Validation of an Annotation Tool for WGS-Based Pharmacogenomics: Preparing for Clinical Implementation in Pediatric Oncology.

01-04-2026

Clinical pharmacology and therapeutics

Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

01-03-2026

CPT: pharmacometrics & systems pharmacology

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

01-03-2026

Blood advances

Fludarabine dosing in the youngest children: safety first.

24-02-2026

Clinical pharmacokinetics

Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases.

01-02-2026

Biomedical chromatography : BMC

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates.

01-02-2026

Clinical pharmacology and therapeutics

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing.

01-02-2026

Cancer chemotherapy and pharmacology

Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.

04-01-2026

Journal of pharmaceutical and biomedical analysis

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

15-12-2025

Therapeutic drug monitoring

Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward.

01-12-2025

Clinical pharmacokinetics

Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study.

01-12-2025

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

01-12-2025

Toxicology reports

Accidental tamoxifen ingestion in a two-year-old child without major immediate symptoms: Case report.

01-12-2025

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Measurement of Tralokinumab Concentrations in Serum and Tear Fluid of Atopic Dermatitis Patients and the Relationship With Treatment Response and Ocular Surface Disease.

01-11-2025

British journal of clinical pharmacology

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

26-10-2025

Cancer chemotherapy and pharmacology

Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy-A case report.

22-10-2025

Therapeutic drug monitoring

Stabilization of Abiraterone in Human Plasma Using the Esterase Inhibitor Bis(4-nitrophenyl) Phosphate.

01-10-2025

Therapeutic drug monitoring

Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs.

01-10-2025

Oncology and therapy

Assessing Safety of the Transition to Generic Imatinib in Patients with Gastrointestinal Stromal Tumours.

01-09-2025

Clinical pharmacology and therapeutics

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment.

01-09-2025

Clinical pharmacology and therapeutics

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.

01-08-2025

Biomedical chromatography : BMC

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies.

01-08-2025

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.

01-08-2025

Contemporary clinical trials communications

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).

01-06-2025

Cancer reports (Hoboken, N.J.)

Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient-A Case Report.

01-06-2025

Oncology and therapy

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.

01-06-2025

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.

The insufficient publication of early-phase clinical trials in oncology.

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Unexpected Lack of Efficacy of Liposomal-Encapsulated Daunorubicin/Cytarabine in Pediatric FLT3 Wild-Type Newly Diagnosed AML.

Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review.

Prestin as a potential biomarker for cochlear injury: Current evidence and future directions.

Extrapolating Vincristine-Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias.

Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.

The impact of pazopanib and extremity radiotherapy on transaminase elevations in soft tissue sarcoma.

Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC.

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.

Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

Transfer of trastuzumab and pertuzumab into human breast milk: a case report.

Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours.

Risk factors for alloimmune lung syndromes after allogeneic hematopoietic cell transplantation in children.

Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report.

Analytical Validation of an Annotation Tool for WGS-Based Pharmacogenomics: Preparing for Clinical Implementation in Pediatric Oncology.

Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

Fludarabine dosing in the youngest children: safety first.

Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases.

An Overview of Liquid Chromatography-Mass Spectrometry (LC-MS) Methods for the Quantification of Antibody-Drug Conjugates.

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing.

Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward.

Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study.

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

Accidental tamoxifen ingestion in a two-year-old child without major immediate symptoms: Case report.

Measurement of Tralokinumab Concentrations in Serum and Tear Fluid of Atopic Dermatitis Patients and the Relationship With Treatment Response and Ocular Surface Disease.

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy-A case report.

Stabilization of Abiraterone in Human Plasma Using the Esterase Inhibitor Bis(4-nitrophenyl) Phosphate.

Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs.

Assessing Safety of the Transition to Generic Imatinib in Patients with Gastrointestinal Stromal Tumours.

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment.

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies.

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).

Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient-A Case Report.

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.

This site uses cookies